XCellCure
As a specialist in Cardiology, cell biology, and molecular biology, Dr. Theo van Berkel serves as a leading expert at Leiden University. Dr. van Biessen has contributed groundbreaking discoveries to the field of cardiac biomarker use in risk assessment, particularly regarding prognostic value of CCL3, CCL5, and CCL18. He serves as Head of Department at Leiden University's Biopharmaceuticals & Atherosclerosis Center for Drug Research in addition to his contributions at XCelLCure.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
XCellCure
Patented portable detection device guiding therapeutic prevention of disease preventing the first and fatal heart attack guiding treatment.